Literature DB >> 10720271

AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis.

B L Banwell1, A G Engel.   

Abstract

OBJECTIVE: To study the expression of the small heat shock protein, alphaB-crystallin (alphaBC), in inclusion body myositis (IBM).
BACKGROUND: In humans, alphaBC is constitutively expressed in the eye lens, muscle, and heart, but not in lymphoid tissues. Induced expression of alphaBC occurs under metabolic stress, in virus-infected lymphocytes, and in degenerative brain lesions, including neurofibrillary tangles and senile plaques in AD. The previously reported pathologic similarities between AD and IBM prompted us to study alphaBC expression in IBM.
METHODS: Immunolocalization of alphaBC in muscle of 11 patients with IBM, 50 patients with other muscle diseases, and 4 controls; and quantitative analysis of the frequency of fibers with 1) increased alphaBC expression in IBM and polymyositis and 2) structural abnormality (vacuolated, non-necrotic and invaded by mononuclear cells, Congo red-positive, SMI-31 positive, and ubiquitin positive) in IBM.
RESULTS: We detected enhanced expression of alphaBC not only in all structurally abnormal IBM fibers, but also, and with severalfold higher frequency, in IBM fibers without significant structural abnormality (X fibers) (p values in paired t-tests < 0.001). We also found enhanced alphaBC in abnormal fibers in other diseases; X fibers, however, were extremely sparse or absent, except in two atypical cases of polymyositis refractory to immunotherapy.
CONCLUSION: That the X fibers are much more frequent than the structurally abnormal fibers in IBM points to a pathogenic stressor acting upstream to the development of structural abnormalities. The identification of this stressor is now of paramount importance for deciphering the enigma of IBM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720271     DOI: 10.1212/wnl.54.5.1033

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Comparison of the small heat shock proteins alphaB-crystallin, MKBP, HSP25, HSP20, and cvHSP in heart and skeletal muscle.

Authors:  Nikola Golenhofen; Ming Der Perng; Roy A Quinlan; Detlev Drenckhahn
Journal:  Histochem Cell Biol       Date:  2004-10-12       Impact factor: 4.304

2.  Screening for transglutaminase-catalyzed modifications by peptide mass finger printing using multipoint recalibration on recognized peaks for high mass accuracy.

Authors:  Cecilia Sundby Emanuelsson; Sandor Boros; Karin Hjernoe; Wilbert C Boelens; Peter Hojrup
Journal:  J Biomol Tech       Date:  2005-09

Review 3.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

4.  Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis.

Authors:  Kenneth C Parker; Sek Won Kong; Ronan J Walsh; Mohammad Salajegheh; Behzad Moghadaszadeh; Anthony A Amato; Remedios Nazareno; Yin Yin Lin; Bryan Krastins; David A Sarracino; Alan H Beggs; Jack L Pinkus; Steven A Greenberg
Journal:  Muscle Nerve       Date:  2009-06       Impact factor: 3.217

Review 5.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 6.  Therapeutic potential of heat shock protein induction for muscular dystrophy and other muscle wasting conditions.

Authors:  Savant S Thakur; Kristy Swiderski; James G Ryall; Gordon S Lynch
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-19       Impact factor: 6.237

7.  Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Authors:  Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

Review 8.  Caenorhabditis elegans as a model organism to study APP function.

Authors:  Collin Y Ewald; Chris Li
Journal:  Exp Brain Res       Date:  2011-10-29       Impact factor: 1.972

9.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

Authors:  Marinos C Dalakas; Goran Rakocevic; Jens Schmidt; Mohammad Salajegheh; Beverly McElroy; Michael O Harris-Love; Joseph A Shrader; Ellen W Levy; James Dambrosia; Robert L Kampen; David A Bruno; Allan D Kirk
Journal:  Brain       Date:  2009-05-19       Impact factor: 13.501

10.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.